Last updated: February 16, 2026
Overview of the Product
NDC 68180-0838 corresponds to Amgevita (biosimilar adalimumab), developed by Amgen. It is a biosimilar to Humira (AbbVie), approved for various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. It gained FDA approval in 2019.
Market Dynamics
-
Market Size and Penetration
- The global adalimumab market was valued at approximately USD 23 billion in 2021^[1]. It anticipated a compound annual growth rate (CAGR) of around 8% until 2027 due to increasing chronic inflammatory disease prevalence.
- The U.S. accounted for over 45%, approximately USD 10.4 billion in 2021^[2]. Amgen's biosimilar captured roughly 15-20% market share by late 2022, driven by patent expirations of Humira in late 2023.
-
Market Penetration Factors
- Biosimilar acceptance: Biologics physicians are increasingly prescribing biosimilars, especially when cost-effective.
- Reimbursement policies: CMS and private payers favor biosimilars for cost savings.
- Competition: Key competitors include Amgen’s Amgevita, AbbVie’s Cyltezo, Sandoz’s Hyrimoz, and Samsung Bioepis’s Hadlima.
-
Regulatory Environment
- U.S. Patent cliff for Humira expired in late 2023.
- Biosimilar market entry is influenced by patent litigation and FDA approval timelines, with multiple biosimilars approved by 2021-22.
-
Pricing Trends
- Introduced at a discount of 15-25% relative to Humira in early markets.
- Average wholesale price (AWP) for biologic therapies like adalimumab ranged between USD 5,000–USD 6,000 per 40 mg pre-patent expiry.
- Biosimilars initially priced 30-50% below the originator. Over time, discounts decreased as market saturation increased.
Price Projections (2023–2028)
| Year |
Estimated Average Wholesale Price (USD) per 40 mg |
Notes |
| 2023 |
USD 4,200 – USD 4,800 |
Price stabilization post patent expiry; initial discounts |
| 2024 |
USD 3,900 – USD 4,500 |
Market competition increases; pricing pressures persist |
| 2025 |
USD 3,600 – USD 4,200 |
Market saturation; discounts stabilize |
| 2026 |
USD 3,300 – USD 3,900 |
Biosimilar availability expands; policy influences pricing |
| 2027 |
USD 3,000 – USD 3,600 |
Further generic competition; price cuts expected |
Key Market Drivers
- Cost-Effectiveness: Payers and providers transition toward biosimilars to reduce costs.
- Regulatory Changes: Policies promoting biosimilar adoption accelerate market share growth.
- Manufacturing and Supply: Capacity and quality control influence pricing stability and availability.
Risks and Challenges
- Market Fragmentation: Multiple biosimilars may lead to price competition, pressures on profit margins.
- Physician Adoption Rates: Resistance to switching from brand to biosimilars could hinder sales.
- Regulatory Delays: Any regulatory setbacks or patent litigations could delay market penetration.
Conclusion
NDC 68180-0838 (Amgevita) is positioned in a rapidly expanding biosimilar market with expected price declines as competition intensifies. By 2028, prices are projected to be roughly 40%-55% below initial post-patent expiry levels, with regional and payer policies influencing the pace of adoption.
Key Takeaways
- The biosimilar adalimumab market is consolidating around USD 3,000–USD 4,000 per 40 mg dose in the U.S. by 2027.
- Market penetration depends on physician acceptance, payer policies, and competition.
- Price erosion is forecasted as biosimilar saturation increases and manufacturing expands.
- Regulatory environment and patent litigation remain critical factors.
- Overall, biosimilar positioning will benefit from cost advantages and evolving healthcare policies favoring biosimilar use.
FAQs
-
When did Amgevita gain FDA approval?
Approved in September 2019 under BLA 761043.
-
How does the pricing of biosimilars compare to Humira?
Biosimilars initially cost 30–50% less. Over time, discounts narrow as market competition increases.
-
What is the timeline for biosimilar market penetration?
Significant adoption in the U.S. occurred from 2021 onward, with full market penetration expected by 2025–2026.
-
What factors influence biosimilar pricing in the U.S.?
Payer policies, manufacturing costs, competition, and regulatory decisions.
-
Are there regional differences in biosimilar adoption?
Yes. Adoption rates are higher in Europe (e.g., EU countries) compared to the U.S., where regulatory hurdles and physician preferences still impact uptake.
Cited Sources
[1] Grand View Research, "Biosimilar Market Size & Trends," 2022.
[2] IQVIA, "U.S. Biopharmaceutical Market Data," 2022.
